Access

Technical Report

Nature Medicine 15, 1224 - 1228 (2009)
Published online: 4 October 2009 | doi:10.1038/nm.1990

Development of universal antidotes to control aptamer activity

Sabah Oney1,2,3,7, Ruby T S Lam4, Kristin M Bompiani1,2,3, Charlene M Blake1,2,3, George Quick1, Jeremy D Heidel5, Joanna Yi-Ching Liu5, Brendan C Mack6, Mark E Davis6, Kam W Leong4 & Bruce A Sullenger1,2,3

With an ever increasing number of people taking numerous medications, the need to safely administer drugs and limit unintended side effects has never been greater. Antidote control remains the most direct means to counteract acute side effects of drugs, but, unfortunately, it has been challenging and cost prohibitive to generate antidotes for most therapeutic agents. Here we describe the development of a set of antidote molecules that are capable of counteracting the effects of an entire class of therapeutic agents based upon aptamers. These universal antidotes exploit the fact that, when systemically administered, aptamers are the only free extracellular oligonucleotides found in circulation. We show that protein- and polymer-based molecules that capture oligonucleotides can reverse the activity of several aptamers in vitro and counteract aptamer activity in vivo. The availability of universal antidotes to control the activity of any aptamer suggests that aptamers may be a particularly safe class of therapeutics.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Turning aptamers into anticoagulants

Nature Biotechnology News and Views (01 Nov 2004)

Medicine RNA as drug and antidote

Nature News and Views (05 Sep 2002)

RESEARCH

RNA aptamers as reversible antagonists of coagulation factor IXa

Nature Letters to Editor (05 Sep 2002)

A Novel Antidote-Controlled Anticoagulant Reduces Thrombin Generation and Inflammation and Improves Cardiac Function in Cardiopulmonary Bypass Surgery

Molecular Therapy Original Article

See all 6 matches for Research